Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 12305.17 | 0.8116 | 0.8549 | 2.7728 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10755.145 | 0.9951 | 0.9871 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10755.145 | 0.8952 | 0.7318 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10755.145 | 0.9875 | 0.9676 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10755.145 | 0.9484 | 0.8668 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10755.145 | 0.9870 | 0.9661 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10755.145 | 0.9624 | 0.9027 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10755.145 | 0.9744 | 0.9337 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10755.145 | 0.9679 | 0.9169 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10755.145 | 0.9636 | 0.9059 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12070.145 | 0.9384 | 0.8850 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12070.145 | 0.9164 | 0.8437 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12070.145 | 0.9731 | 0.9499 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12070.145 | 0.9356 | 0.8797 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12070.145 | 0.9396 | 0.8872 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12070.145 | 0.9088 | 0.8296 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12070.145 | 0.8569 | 0.7320 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12070.145 | 0.9459 | 0.8990 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12070.145 | 0.9574 | 0.9206 | 1.0737 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 12112.145 | 0.9883 | 0.9878 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 12112.145 | 0.9412 | 0.9381 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 12112.145 | 1.0156 | 1.0161 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 12112.145 | 0.9722 | 0.9709 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 12112.145 | 0.9322 | 0.9284 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 12112.145 | 1.0132 | 1.0137 | 1.9247 |